INFERR-Iron infusion in haemodialysis study: INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis—a protocol for a prospective open-label blinded endpoint randomised controlled trial

Sandawana William Majoni, Jane Nelson, Darren Germaine, Libby Hoppo, Stephanie Long, Shilpa Divakaran, Brandon E. Turner, Jessica Graham, Cherian Sajiv, Basant Pawar, Geetha Rathnayake, Bianca Heron, Louise Maple‐Brown, Robert A. Batey, Peter S Morris, Jane Davies, David Kiran Fernandes, Madhivanan Sundaram, Asanga Abeyaratne, Yun Hui Sheryl Wong, Paul Lawton, Sean Taylor, Federica Barzi, Alan Cass, for the Inferr study GroupTrials 2021 · DOI

Title: INFERR-Iron infusion in haemodialysis study: INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis—a protocol for a prospective open-label blinded endpoint randomised controlled trial
Abstract: This trial is registered with The Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12620000705987. Registered 29 June 2020.

Introduction: The Anemia Management Dilemma

The INFERR trial addresses a critical gap in nephrology: the safe management of anemia in patients where standard biomarkers of iron stores are confounded by chronic inflammation. Specifically, it focuses on First Nations Australians on maintenance haemodialysis in the Northern Territory, a population frequently excluded from landmark trials like DRIVE and PIVOTAL due to high baseline ferritin levels.

Managing anemia in end-stage kidney disease (ESKD) typically involves Erythropoiesis-Stimulating Agents (ESAs), which require adequate iron to function. Clinicians use two surrogate markers to decide when to give iron: ferritin (reflecting iron stores) and transferrin saturation (TSAT) (reflecting iron availability).

The Ferritin Paradox in Chronic Inflammation

Ferritin is an "acute phase reactant," meaning its levels rise during inflammation regardless of actual iron stores. In First Nations Australians in the Northern Territory, chronic inflammation is prevalent, leading to "hyperferritinaemia" (ferritin > 700 μg/L). Current international guidelines suggest withholding iron when ferritin is this high to avoid potential iron overload and toxicity.

This leaves clinicians in an "evidence-free zone": these patients often have low TSAT (suggesting they need iron) but high ferritin (suggesting they shouldn't have it). Withholding iron may lead to poorly managed anemia and higher, more expensive ESA doses, while giving iron might increase the risk of infections or liver damage. The INFERR trial tests the hypothesis that these patients actually have "functional iron deficiency"—where iron is present but "locked away" by inflammation.

Study Design and Methodology

The study is designed as a prospective, open-label, blinded endpoint randomized controlled trial (PROBE design). It aims to enroll 576 First Nations Australian patients on maintenance haemodialysis across the Northern Territory.

Overview of the INFERR trial design, illustrating the pathway from screening and eligibility criteria to randomization and the 48-month treatment period.

As shown in the trial overview, eligibility requires patients to be on haemodialysis for at least three months, have a hemoglobin level ≤ 115 g/L, and ferritin levels between 700 and 2000 μg/L with TSAT < 40%. This design specifically targets the population currently underserved by existing global guidelines that set a "ceiling" for iron therapy at 500–800 μg/L.

Treatment Allocation and Intervention Logic

Participants are randomized into two arms to compare active intervention against standard care:

Detailed treatment allocation logic for Arm A (Intervention) and Arm B (Control) based on monthly ferritin and TSAT levels.
  • Intervention (Arm A): 400 mg of IV iron polymaltose administered monthly. Iron is withheld if pre-dose ferritin exceeds 2000 μg/L or TSAT reaches ≥ 40%.
  • Control (Arm B): No IV iron treatment (standard care), unless ferritin drops below 700 μg/L.

While the trial is open-label for clinicians and patients, the "adjudicators" who assess the primary outcomes (death and infection-related hospitalizations) are blinded to the treatment group to reduce bias. Additionally, a subset of patients will undergo FerriScan (MRI) to non-invasively measure actual liver iron concentration, providing a "gold standard" check against the surrogate blood markers.

Cultural Integration and Expected Impact

A unique aspect of the INFERR trial is its integration of First Nation Reference Groups (FNRG) to ensure the research is conducted in a culturally safe and respectful manner.

The study is powered (80%) to detect a 30% reduction in the primary composite endpoint: the risk of all-cause death or hospitalization with a principal diagnosis of infection. The researchers also aim to determine if IV iron allows for a reduction in ESA doses, which would have significant economic implications for the healthcare system. By pushing the ferritin ceiling to 2000 μg/L, INFERR seeks to establish a new evidence-based standard for anemia management in populations with high inflammatory burdens.

Summary updated

Abstract

This trial is registered with The Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12620000705987 . Registered 29 June 2020.
BibTeX
@inproceedings{majoni2021inferr,
  author = {Sandawana William Majoni and Jane Nelson and Darren Germaine and Libby Hoppo and Stephanie Long and Shilpa Divakaran and Brandon E. Turner and Jessica Graham and Cherian Sajiv and Basant Pawar and Geetha Rathnayake and Bianca Heron and Louise Maple‐Brown and Robert A. Batey and Peter S Morris and Jane Davies and David Kiran Fernandes and Madhivanan Sundaram and Asanga Abeyaratne and Yun Hui Sheryl Wong and Paul Lawton and Sean Taylor and Federica Barzi and Alan Cass and for the INFERR study Group},
  title = {{INFERR-Iron infusion in haemodialysis study: INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis—a protocol for a prospective open-label blinded endpoint randomised controlled trial}},
  booktitle = {Trials},
  year = {2021},
  doi = {10.1186/s13063-021-05854-w},
}
Figure